Evidence map›Paper›PMID 25093277›Full record

ReviewNutrients2014

Hepcidin and iron homeostasis during pregnancy.

Mary Dawn Koenig, Lisa Tussing-Humphreys, Jessica Day, Brooke Cadwell, Elizabeta Nemeth

Registry-linked trialOpen access · goldAbstract readReview
In one paragraph

Review in Nutrients, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03706638 (Daily vs. Intermittent Iron Therapy in Iron Deficient Pregnant Patients), which is not on this map. Cited by 91 papers.

0numbers the graph read from it
0cells of the map it votes in
91citing papers in PubMed
7.0field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03706638 nacompletednot on this mapstarted 2018, after this paper: background citation

Daily vs. Intermittent Iron Therapy in Iron Deficient Pregnant Patients: A Randomized Noninferiority Trial

TypeinterventionalSponsorUConn HealthRan2018 to 2020Enrolled46ConditionsIron Deficiency Anemia of PregnancyArmsFerrous Sulfate
3 · Its place in the literature

Who cites it

91 citing papers in PubMed, 177 citations in OpenAlex.

  1. Trial
  2. Trial
  3. Trial
  4. Trial
  5. Malaria early in the first pregnancy: Potential impact of iron status.Clinical nutrition (Edinburgh, Scotland) · 2020
    Trial
  6. Trial
  7. Trial
  8. Trial
  9. Trial
  10. Gestational Changes in Placental Iron Homeostasis are Associated With Ferroptosis-Associated Redox Signaling and Trophoblast Behavior.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2026
    Article
  11. Article
  12. Article
  13. Observational
  14. Article
  15. Article
  16. Article
  17. Review
  18. Understanding hepcidin for iron management in pregnancy.Transfusion medicine (Oxford, England) · 2025
    Review
  19. Review
  20. Article

31 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 4 institutions in 1 country.

Mary Dawn KoenigDepartment of Women, Children and Family Health Science, College of Nursing, University of Illinois at Chicago 845 S. Damen Ave., Room 814 (MC802), Chicago, IL 60612, USA. marydh@uic.edu.
Lisa Tussing-HumphreysDivision of Health Promotion Research, Department of Medicine, University of Illinois at Chicago, Chicago, IL 60608, USA. ltussing@uic.edu.
Jessica DaySumter Family Health Center, 1278 N Lafayette Drive Sumter, SC 29150, USA. jday@sumterfhc.com.
Brooke CadwellSchool of Nursing, Yale University, 100 Church Street South, New Haven, CT 06519, USA. brooke.cadwell@yale.edu.
Elizabeta NemethUCLA, Department of Medicine, Center for Iron Disorders, University of California Los Angeles, CHS 52-239, 10833 Le Conte Ave. Los Angeles, CA 90095-1690, USA. enemeth@mednet.ucla.edu.
University of California, Los Angeles · USUniversity of Illinois Chicago · USUniversity of Illinois Urbana-Champaign · USYale University · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Hepcidin is the master regulator of systemic iron bioavailability in humans. This review examines primary research articles that assessed hepcidin during pregnancy and postpartum and report its relationship to maternal and infant iron status and birth outcomes; areas for future research are also discussed. A systematic search of the databases Medline and Cumulative Index to Nursing and Allied Health returned 16 primary research articles including 10 human and six animal studies. Collectively, the results indicate that hepcidin is lower during pregnancy than in a non-pregnant state, presumably to ensure greater iron bioavailability to the mother and fetus. Pregnant women with undetectable serum hepcidin transferred a greater quantity of maternally ingested iron to their fetus compared to women with detectable hepcidin, indicating that maternal hepcidin in part determines the iron bioavailability to the fetus. However, inflammatory states, including preeclampsia, malaria infection, and obesity were associated with higher hepcidin during pregnancy compared to healthy controls, suggesting that maternal and fetal iron bioavailability could be compromised in such conditions. Future studies should examine the relative contribution of maternal versus fetal hepcidin to the control of placental iron transfer as well as optimizing maternal and fetal iron bioavailability in pregnancies complicated by inflammation.

Indexed as

AnimalsBiological AvailabilityDatabases, FactualDisease Models, AnimalFemaleFetal BloodHepcidinsHomeostasisHumansIronMaternal-Fetal ExchangePostpartum PeriodPregnancyHepcidinsIron

Identifiers

PMID25093277
PMCPMC4145295
OpenAlexW2142754173

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.